Skip to main content

Table 1 Characteristics of Studies Included

From: Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis

Author Year Country City Design HBOC/HBC Age at Diagnosis (range or mean) Mutation type Test type Sample size Sample size of HBOC
Abdel-Razeq 2018 Jordan Pilot study HBCb 22–75 Deleterious
Suspected-deleterious
BART1 100 84
Bu 2016 Saudi Arabia Cross-sectional HBC 41.9 Deleterious PCR2, CS3/SS4, and TCS5 818 60
Bujassoum 2017 Qatar Retroa HBC 23–68 Deleterious MLPA6 82 82
Cherbal 2015 Algeria High Plains Cross-sectional HBOCc < 50 Deleterious
VUS
PCR2 192 192
El Saghir 2015 Lebanon Beirut Cross-sectional HBC 40.8 Deleterious
VUS
MLPA6 250 74
Ibrahim 2010 Egypt Alexandria Registry data HBC 43.5 Deleterious SSCP7
HAC8
60 39
Jalkh 2012 Lebanon Cross-sectional HBC 41 Deleterious
VUS
Polymorphisms
Fluorescent DS9 72 72
Kadouri 2007 Palestine East Jerusalem Cross-sectional HBC Deleterious
VUS
Polymorphisms
DHPLC10 31 10
Laarabi 2017 Morocco North-East morocco (Rabat, Fes, Oujda) Cross-sectional HBOC Deleterious CSS11
NGS12
TS13
122 122
Laraqui 2013 Morocco Rabat Retro HBC Deleterious DS14 121 19
Mahfoudh 2012 Tunisia Sousse Cross-sectional HBC 29–65 Deleterious
VUS
Polymorphisms
DS15 24 24
Riahi 2016 Tunisia Cross-sectional HBC Deleterious Logistic regression model (studied three studies) 92 92
Tazzite 2012 Morocco Casablanca Case series HBOC 25–60 Deleterious DS15 40 34
Uhrhammer 2008 Algeria Algiers Pilot study HBC 15–52 Deleterious
VUS
Polymorphisms
PCR2 64 13
  1. aRetro: retrospective cohort study
  2. bHBC: hereditary breast cancer
  3. cHBOC: hereditary breast and/or ovarian cancer
  4. 1BART: Comprehensive BRACAnalysis and BRACAnalysis rearrangement test
  5. 2PCR: Polymerase chain reaction
  6. 3CS: Capture sequencing
  7. 4SS: Sanger sequencing
  8. 5TCS: Targeted capture sequencing
  9. 6MLPA: Multiple ligation dependent probe amplification
  10. 7SSCP: single strand conformation polymorphism assay
  11. 8HAC: Heteroduplex assay confirmation
  12. 9Fluorescent direct sequencing of the entire coding region and intronic sequence flanking each exon
  13. 10DHPLC: denaturing high performance liquid chromatography
  14. 11CSS: Conventional individual exon-by-exon Sanger sequencing
  15. 12NGS: Next generation sequencing
  16. 13TS: Target screening for exon 10 in BRCA2
  17. 14Direct sequencing of all coding exons and flanking intron sequences of the BRCA1 gene
  18. 15DS: Direct Sequencing
  19. 16Direct sequencing